LATEST

• REGULATORY Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
  March 17, 2026

• BUSINESS Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
  March 17, 2026

• BUSINESS ADDP, Proteros Tie Up to Expand Drug Discovery Support
  March 17, 2026

• BUSINESS Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
  March 17, 2026

• BUSINESS Olumiant Gains Oral Suspension Formulation in Japan
  March 17, 2026

• REGULATORY Gaku Hashimoto to Return as Skipper of LDP Team on Drug Innovation
  March 17, 2026

• BUSINESS BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
  March 17, 2026

• REGULATORY Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
  March 16, 2026

• REGULATORY Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
  March 16, 2026

• REGULATORY LDP Urges Action on Drug Supply Risks Linked to Reliance on Specific Countries
  March 16, 2026

• BUSINESS Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
  March 16, 2026

• BUSINESS AbbVie Japan Files Rinvoq for Vitiligo
  March 16, 2026

• BUSINESS SSP Appoints Yoko Motoshima as New President
  March 16, 2026

• BUSINESS PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
  March 13, 2026

• BUSINESS Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
  March 13, 2026

• BUSINESS Fujifilm Invests in Austria’s Valanx Biotech to Boost ADC Technology
  March 13, 2026

• BUSINESS Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
  March 13, 2026

• BUSINESS Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
  March 13, 2026

• REGULATORY 874 Defects or Health Damages Reported for Regenerative Medical Products in 1H FY2025
  March 13, 2026

• REGULATORY Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
  March 12, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• …
• Next ›
• 最終 »